임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-14 01:21
논문번호 121
논문제목(영문) Recurrent Stent Thrombosis and Pulmonary Thromboembolism Associated with Hyperhomocysteinemia.
국내외구분 국내 SCI여부 KCI
연구책임자역할 교신저자
주저자명 Kim MC
교신저자명 Jeong MH
공동저자명 Kim MC, Jeong MH, Jang Sy, Choi HS, Cho KH, Hwang SH, Lee MG, Park KH, Sim DS, Hong YJ, Kim JH, Ahn Y, Kang JC;
게제년월일 2012-09-15
ISSN 2287-2892
Impact Factor 0
학술지명 J Lipid Atheroscler
서지사항 0집 / 1권 / 2호,   페이지(95 - 100)
요약초록문
(Abstract) 입력		 BACKGROUND/AIMS:
To determine which drug-eluting stents are more effective in acute myocardial infarction (MI) patients with chronic kidney disease (CKD).
METHODS:
This study included a total of 3,566 acute MI survivors with CKD from the Korea Acute Myocardial Infarction Registry who were treated with stenting and followed up for 12 months: 1,845 patients who received sirolimus-eluting stents (SES), 1,356 who received paclitaxel-eluting stents (PES), and 365 who received zotarolimus-eluting stents (ZES). CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m(2) calculated by the modification of diet in renal disease method.
RESULTS:
At the 12-month follow-up, patients receiving ZES demonstrated a higher incidence (14.8%) of major adverse cardiac events (MACEs) compared to those receiving SES (10.1%) and PES (12%, p = 0.019). The ZES patients also had a higher incidence (3.9%) of target lesion revascularization (TLR) compared to those receiving SES (1.5%) and PES (2.4%, p = 0.011). After adjusting for confounding factors, ZES was associated with a higher incidence of MACE and TLR than SES (adjusted hazard ratio [HR], 0.623; 95% confidence interval [CI], 0.442 to 0.879; p = 0.007; adjusted HR, 0.350; 95% CI, 0.165 to 0.743; p = 0.006, respectively), and with a higher rate of TLR than PES (adjusted HR, 0.471; 95% CI, 0.223 to 0.997; p = 0.049).
CONCLUSIONS:
Our findings suggest that ZES is less effective than SES and PES in terms of 12-month TLR, and has a higher incidence of MACE due to a higher TLR rate compared with SES, in acute MI patients with CKD.
파일  C121.+J+Lipid+Atheroscler+2012;1(2)95-100..pdf (4.2M) DATE : 2021-05-25 15:23:52